Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Leukemia, Myeloid, Acute 967Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Leukemia, Lymphocytic, Chronic, B-Cell 555Leukemia 486Myelodysplastic Syndromes 375Lymphoma, Non-Hodgkin 347Lymphoma 297Lymphoma, Mantle-Cell 263Hematologic Neoplasms 260Lymphoma, Follicular 256Lymphoma, Large B-Cell, Diffuse 253Burkitt Lymphoma 232Lymphoma, B-Cell, Marginal Zone 227Recurrence 216Hodgkin Disease 182Multiple Myeloma 172Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 159Lymphoma, Large-Cell, Immunoblastic 158Leukemia, Myelomonocytic, Chronic 153Leukemia, Myelogenous, Chronic, BCR-ABL Positive 147Waldenstrom Macroglobulinemia 123Lymphoma, T-Cell, Cutaneous 116Neoplasms 112Lymphoma, Large-Cell, Anaplastic 111Blast Crisis 105Congenital Abnormalities 104Immunoblastic Lymphadenopathy 98Mycosis Fungoides 97Sezary Syndrome 96Myeloproliferative Disorders 92

Interventions

ripretinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Mast Cell Activation Disorders × Other hematologic neoplasm × Clear all
NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Deciphera Pharmaceuticals, LLC

Phase 1 Completed
282 enrolled
CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡